loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Baxdrostat

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Baxdrostat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat
    CinCor Announces Receipt of Minutes with FDA on Planned PIII of Baxdrostat

    21 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/21/2612072/0/en/CinCor-Pharma-Announces-Receipt-of-Minutes-from-End-of-Phase-2-Meeting-with-the-U-S-Food-and-Drug-Administration-on-Planned-Phase-3-Program-of-Baxdrostat.html

    GLOBENEWSWIRE
    21 Feb 2023
    Share Share
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal
    AstraZeneca to acquire CinCor Pharma in nearly $2 billion deal

    10 Jan 2023

    // PRESS RELEASE

    https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquire-cincor-for-cardiorenal-asset.html

    PRESS RELEASE
    10 Jan 2023
    Share Share
    CinCor's hypertension drug loses halo after phase 2 fail
    CinCor's hypertension drug loses halo after phase 2 fail

    29 Nov 2022

    // James Waldron FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/cincors-hypertension-drug-loses-its-halo-after-phase-2-fail-plunging-stock-44

    James Waldron FIERCEBIOTECH
    29 Nov 2022
    Share Share
    CinCor Pharma Announces Publication in the NEM of Phase 2 BrigHtn Data
    CinCor Pharma Announces Publication in the NEM of Phase 2 BrigHtn Data

    07 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/07/2550309/0/en/CinCor-Pharma-Announces-Publication-in-the-New-England-Journal-of-Medicine-of-Phase-2-BrigHtn-Data-on-Selective-Aldosterone-Synthase-Inhibitor-Baxdrostat-in-Treatment-Resistant-Hyp.html

    GLOBENEWSWIRE
    07 Nov 2022
    Share Share
    CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat
    CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat

    25 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/25/2540780/0/en/CinCor-Pharma-Announces-Presentation-of-Phase-1-Clinical-Data-for-Baxdrostat-at-the-Upcoming-American-Society-of-Nephrology-Kidney-Week-2022.html

    GLOBENEWSWIRE
    25 Oct 2022
    Share Share
    CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat
    CinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat

    12 Oct 2022

    // CINCOR

    https://www.cincor.com/news-releases/news-release-details/cincor-pharma-announces-oral-presentation-phase-1-data

    CINCOR
    12 Oct 2022
    Share Share